More than 6,000 Michigan COVID-19 patients are currently receiving antibody therapy a week. But two of the three leading drugs on the market don't work against omicron. The state currently has only 4,000 doses of the one that does.
The single remaining monoclonal antibody therapy effective against the variant is now in short supply in the U.S., imperiling an option that doctors and hospitals have relied on.